SEC Form 4 · accession 0001144204-15-008400
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 10, 2015
Accepted (ET)
Feb 12, 2015 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1,F2 | Feb 10, 2015 | S | 5,000 | $6.389 | D | 1,680,388 | I | See Footnote |
| Common Stock, par value $0.0001F2 | Feb 11, 2015 | S | 10,000 | $6.40 | D | 1,670,388 | I | See Footnote |
| Common Stock, par value $0.0001F3,F2 | Feb 12, 2015 | S | 23,000 | $6.401 | D | 1,647,388 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 5,000 shares in 2 separate transactions, ranging from $6.370 to $6.500 per share, resulting in a weighted average sale price per share of $6.389. The Reporting Persons undertake to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2Represents shares of the Issuer's common stock held by Eses Holdings (FZE), a corporation organized under the laws of Sharjah, United Arab Emirates ("Eses"). Ahmed Shayan Fazlur Rahman is the sole shareholder of Eses, and possesses the power to vote and the power to direct the disposition of all securities of the Issuer held by Eses.
- F3Represents the sale of 23,000 shares in 3 separate transactions, ranging from $6.400 to $6.402 per share, resulting in a weighted average sale price per share of $6.401. The Reporting Persons undertake to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.